ArticleOncotarget2016

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Hinrich P Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.